ISBN: 9780313398223

"Reproductive Rights and the FDA: The Battles over the Birth-Control, RU-486, and Morning-After Pills and the Gardasil Vaccine" tackles a subject that remains controversial more than 60 y… More...

"Reproductive Rights and the FDA: The Battles over the Birth-Control, RU-486, and Morning-After Pills and the Gardasil Vaccine" tackles a subject that remains controversial more than 60 years after "the pill" was approved for use in the United States. The first book to examine the politicization of the FDA approval process for reproductive drugs, this study maps the hard-fought battles over the four major drugs currently on the U.S. market. To make her case, Melissa Haussman scrutinizes the history of the FDA and the statutes that have governed it, as well as interactions between the U.S. government, American pharmaceutical companies, and the medical community. The analysis centers on explaining how three reproductive drugs were kept off the U.S. market well after their efficacy had been proven, while the availability of the fourth, Gardasil, has less to do with helping girls than with preserving the financial wellbeing of Merck. Readers will come away understanding how, when it comes to reproductive drugs, women's health concerns have consistently taken a backseat to political agendas and corporate profits. Media > Book, [PU: Greenwood Press]<

ISBN: 9780313398223

"Reproductive Rights and the FDA: The Battles over the Birth-Control, RU-486, and Morning-After Pills and the Gardasil Vaccine" tackles a subject that remains controversial more than 60 y… More...

"Reproductive Rights and the FDA: The Battles over the Birth-Control, RU-486, and Morning-After Pills and the Gardasil Vaccine" tackles a subject that remains controversial more than 60 years after "the pill" was approved for use in the United States. The first book to examine the politicization of the FDA approval process for reproductive drugs, this study maps the hard-fought battles over the four major drugs currently on the U.S. market. To make her case, Melissa Haussman scrutinizes the history of the FDA and the statutes that have governed it, as well as interactions between the U.S. government, American pharmaceutical companies, and the medical community. The analysis centers on explaining how three reproductive drugs were kept off the U.S. market well after their efficacy had been proven, while the availability of the fourth, Gardasil, has less to do with helping girls than with preserving the financial wellbeing of Merck. Readers will come away understanding how, when it comes to reproductive drugs, women's health concerns have consistently taken a backseat to political agendas and corporate profits. Media >, [PU: Greenwood Press]<